Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Pseudomonas aeruginosa serotype IATS O11 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C38714H60189N10637O12187S322 |
Molar mass | 879959.96 g·mol−1 |
![]() ![]() |
Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa. [1]
It is a fully human pentameric IgM antibody with a mouse J chain. [1]
Panobacumab is being developed by Aridis Pharmaceuticals. As of November 15th it is in phase 2 clinical trials. The originator was Berna Biotech. [2]
The mechanism of action is as a lipopolysaccharide inhibitor. [2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Pseudomonas aeruginosa serotype IATS O11 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C38714H60189N10637O12187S322 |
Molar mass | 879959.96 g·mol−1 |
![]() ![]() |
Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa. [1]
It is a fully human pentameric IgM antibody with a mouse J chain. [1]
Panobacumab is being developed by Aridis Pharmaceuticals. As of November 15th it is in phase 2 clinical trials. The originator was Berna Biotech. [2]
The mechanism of action is as a lipopolysaccharide inhibitor. [2]